U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H35N5O5
Molecular Weight 581.6628
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERGOTAMINE

SMILES

C[C@@]1(C(=O)N2[C@@]([H])(Cc3ccccc3)C(=O)N4CCC[C@@]4([H])[C@]2(O)O1)N=C([C@]5([H])C=C6c7cccc8c7c(C[C@@]6([H])N(C)C5)c[nH]8)O

InChI

InChIKey=XCGSFFUVFURLIX-VFGNJEKYSA-N
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

HIDE SMILES / InChI

Molecular Formula C33H35N5O5
Molecular Weight 581.6628
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

The isolation and naming of ergotamine by Stoll occurred in 1925 but the complete elucidation of structure was not achieved until 1951, with synthesis following some 10 years later. Current sources of ergotamine include the isolation from field ergot and fermentation broth, as well as synthesis via coupling of (+)-lysergic acid with the appropriate synthetic peptidic moiety. Ergotamine was introduced into world commerce in 1921, and is currently marketed as its water soluble tartrate salt. Ergotamine is a partial agonist at various tryptaminergic receptors (including the serotonin receptor [5-HT2]) and at various α-adrenergic receptors in blood vessels and various smooth muscles. It is likely that the major activity of ergotamine and related alkaloids is one of agonism at the 5-HT1B/1D receptors, just as with the “triptan” antimigraine compounds. FDA-labeled indications for ergotamine tartrate are in the abortion or prevention of vascular headaches, such as migraine, migraine variant, cluster headache, and histaminic cephalalgia.

Originator

Curator's Comment:: In 1918 Arthur Stoll patented the isolation of ergotamine tartrate, which was subsequently marketed by Sandoz in 1921.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ERGOMAR

Approved Use

Ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or a so-called "histaminic cephalalgia".

Launch Date

4.1472E11
Primary
CAFERGOT

Approved Use

Treatment of acute attacks of migraine with or without aura in adults.
Primary
MIGERGOT

Approved Use

MIGERGOT is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia.” Ergotamine tartrate and caffeine suppositories should only be used for migraine headaches as they are not effective for other types of headaches and they lack analgesic properties.

Launch Date

4.33987191E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
21.4 pg/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
454 pg/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.38 ng × h/mL
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
61 pg × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.36 ng × h/mL
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.04 ng × h/mL
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1216 pg × h/mL
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.15 h
3.89 μg/kg bw single, intravenous
dose: 3.89 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.08 h
1.01 μg/kg bw single, intravenous
dose: 1.01 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.13 h
1.94 μg/kg bw single, intravenous
dose: 1.94 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.35 h
2 mg single, rectal
dose: 2 mg
route of administration: Rectal
experiment type: SINGLE
co-administered:
ERGOTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting (severe)
Dizziness
Blood pressure decreased
Peripheral vasoconstriction
Paresthesia
Cyanosis peripheral
Angina
Sources:
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Disc. AE: Depression, Vertigo...
AEs leading to
discontinuation/dose reduction:
Depression
Vertigo
Blurred vision
Arrhythmia
Hypersensitivity
Migraine aggravated
Urticaria
Dyspnoea
Fatigue
Tachycardia
Vagal reaction
Dizziness
Tinnitus
Sources: Page: p.319
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Disc. AE: Nausea, Lightheadedness...
AEs leading to
discontinuation/dose reduction:
Nausea (2.4%)
Lightheadedness (2.4%)
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Angina Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Blood pressure decreased Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Cyanosis peripheral Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Dizziness Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Nausea Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Paresthesia Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Peripheral vasoconstriction Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Vomiting severe
Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Co-administed with::
caffeine, p.o(2000 mg, single)
Sources:
healthy, 21
n = 1
Health Status: healthy
Age Group: 21
Sex: F
Population Size: 1
Sources:
Arrhythmia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Blurred vision Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Depression Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Dizziness Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Dyspnoea Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Fatigue Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Hypersensitivity Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Migraine aggravated Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Tachycardia Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Tinnitus Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Urticaria Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Vagal reaction Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Vertigo Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Co-administed with::
caffeine, p.o(200 mg, single)
Sources: Page: p.319
unhealthy, 40+/-10
n = 289
Health Status: unhealthy
Condition: Migraine
Age Group: 40+/-10
Sex: M+F
Population Size: 289
Sources: Page: p.319
Lightheadedness 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Nausea 2.4%
Disc. AE
2 mg single, oral
Recommended
Dose: 2 mg
Route: oral
Route: single
Dose: 2 mg
Sources: Page: p.2
unhealthy
n = 41
Health Status: unhealthy
Condition: Migraine
Sex: M+F
Population Size: 41
Sources: Page: p.2
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 13 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities
PubMed

PubMed

TitleDatePubMed
A case of multiple arterial thromboses after oral contraceptives and ergotamine.
1967 Apr
Upper limb ischaemia due to ergotamine tartrate.
1970 Jul
[Severe generalized arteriospasm after a minimal therapeutic dose of ergotamine].
1972 Dec 14
[Severe arterial spasms after the use of Ergotamine].
1972 Feb 8
[Spasms of the main muscular arteries in the extremities following ingestion of ergotamine-containing drugs].
1973 Apr 20
Arterial spasm associated with oral ergotamine therapy.
1973 Dec
Ergotism. Unilateral brachial artery thrombosis secondary to ergotamine tartrate.
1973 Jun
[Acute ischemia of the lower limbs due to ergotamine-induced arteriospasm].
1973 Nov 30
[Chronic ergotamine poisoning after migraine treatment].
1974
Ergotamine-induced venous thrombosis.
1974 Apr
Ischaemic lateral popliteal nerve palsy due to ergot intoxication.
1974 Dec
Letter: Ergotamine-induced headaches.
1974 Jun 29
Letter: Rebound migraine.
1974 May 11
[Ergotamine as a cause of arterial insufficiency].
1974 Oct 10
Peripheral vascular spasm due to ergotamine tartrate.
1977 Dec
[Alarming course of drug-induced ergotism following prolonged use of ergotamine tartatare].
1977 Feb 18
Myocardial ischaemia in migraine sufferers taking ergotamine.
1978 Jan
Adverse effects of ergotamine. Blood circulation disorders--increased headache.
1978 Jan 10
Angina pectoris and sudden death in the absence of atherosclerosis following ergotamine therapy for migraine.
1979 Jul
[Non-invasive method for recognition of coronary artery spasm: 201thallium sequential scintigraphy of the myocardium after ergotamine provocation (author's transl)].
1980 Apr 11
Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.
1980 Dec 13
Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm.
1981 Jun
[A case report of acute myocardial infarction induced by ergotamine tartrate (author's transl)].
1981 Mar
Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations.
1982 Dec
Arterial complications of migraine treatment with methysergide and parenteral ergotamine.
1982 Jul 24
Myocardial infarction following administration of sublingual ergotamine.
1982 Sep
[Myocardial infarct during ergotamine medication in a young man with normal coronary arteries].
1983 Apr 22
Severe vascular spasm due to erythromycin-ergotamine interaction.
1984 Jun
Screening for new compounds with antiherpes activity.
1984 Oct
Reversible cerebral arteriopathy associated with the administration of ergot derivatives.
1984 Sep
[Ergotism with cerebral complications. Case report and review of the literature].
1986 Apr 5
Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.
1986 Jan
Amelioration of ergotamine withdrawal symptoms with naproxen.
1987 Mar
[Myocardial infarct caused by an ergotamine tartrate-troleandomycin combination].
1988 Sep-Oct
St. Anthony's fire: a medieval disease in modern times: case history.
1989 Oct
[Generalized brain edema and cerebral infarct in ergotamine abuse: imaging by computerized tomography, magnetic resonance tomography and angiography].
1989 Sep
Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature.
1990 Jan
Ergotamine headache mistaken for temporal arteritis.
1990 Sep
Dystonia and reflex sympathetic dystrophy induced by ergotamine.
1991
Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain.
1993 Apr 15
[Daily chronic headache in patients with migraine induced by abuse of ergotamine-analgesics: response due to a protocol of outpatient treatment].
1993 Aug-Sep
Cloning and characterisation of the human 5-HT5A serotonin receptor.
1994 Dec 5
Ergot induced peripheral vascular insufficiency, non-interventional treatment.
1994 Mar
Ergotamine-induced headache can be sustained by sumatriptan daily intake.
1994 Oct
Drug-induced fibrotic valvular heart disease.
2009 Aug 15
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.
2010 Feb
Cytotoxicity and accumulation of ergot alkaloids in human primary cells.
2011 Apr 11
Structural features for functional selectivity at serotonin receptors.
2013 May 3
Structural basis for molecular recognition at serotonin receptors.
2013 May 3
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Patents

Patents

Sample Use Guides

MIGERGOT - ergotamine tartrate and caffeine rectal suppository. One suppository at start of attack; second suppository after 1 hour, if needed for full relief. Two suppositories is the maximum dose for an individual attack. Cafergot (Ergotamine tartrate 1 mg and Caffeine 100 mg Tablets) First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. ERGOMAR SUBLINGUAL- ergotamine tartrate tablet For best results, dosage should start at the first sign of an attack. Early Administration Gives Maximum Effectiveness. At the first sign of an attack or to relieve symptoms after onset of an attack, one 2 mg tablet is placed under the tongue. Another tablet should be taken at half-hour intervals thereafter, if necessary, but dosage must not exceed three tablets in any 24hour period. Total weekly dosage should not exceed five tablets (10 mg) in any one week. Ergomar® Sublingual Tablets should not be used for chronic daily administration.
Route of Administration: Other
In Vitro Use Guide
The bovine anterior pituitary cells were implanted on culture tubes using D-valine minimal essential medium with serum to suppress the overgrowth of fibroblasts and then maintained in L-valine Dulbecco's modified Eagle medium. (3H)-Uridine uptake by these cells was suppressed by ergotamine at a concentration varing from 1-10 uM
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:20:25 UTC 2021
Edited
by admin
on Sat Jun 26 00:20:25 UTC 2021
Record UNII
PR834Q503T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ERGOTAMINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ERGOTAMINE [HSDB]
Common Name English
ERGOTAMINE [VANDF]
Common Name English
ERGOTAMINE [WHO-DD]
Common Name English
ERGOTAMINE [MI]
Common Name English
ERGOTAMINE [INN]
Common Name English
NSC-95090
Code English
ERGOTAMAN-3',6',18-TRIONE, 12'-HYDROXY-2'-METHYL-5'-(PHENYLMETHYL)-, (5'.ALPHA.)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000007621
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NCI_THESAURUS C47794
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NDF-RT N0000007621
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA72
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA52
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA02
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
LIVERTOX 363
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
NDF-RT N0000175766
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-ATC N02CA52
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA02
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
WHO-VATC QN02CA72
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1043
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
INN
391
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
CAS
113-15-5
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
NCI_THESAURUS
C61751
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
EVMPD
SUB06598MIG
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
IUPHAR
149
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
DRUG BANK
DB00696
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
MESH
D004878
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
EPA CompTox
113-15-5
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
FDA UNII
PR834Q503T
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
LACTMED
Ergotamine
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
RXCUI
4025
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M4988
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY Merck Index
PUBCHEM
8223
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
HSDB
4076
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
WIKIPEDIA
ERGOTAMINE
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-023-9
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL442
Created by admin on Sat Jun 26 00:20:25 UTC 2021 , Edited by admin on Sat Jun 26 00:20:25 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY